Haven't used PHusis Therapeutics yet?
Ask AI

Ask AI about PHusis Therapeutics

Generated with AI from 8 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Adeline Andre
Reviews 1

I recently used the services of a pharmaceutical company and I must say that I was very impressed. The level of professionalism displayed by the staff was exceptional, and the quality of their products was outstanding. I would highly recommend their services to anyone in need of pharmaceutical products.

Jose Urioste
Reviews 1

PHusis Therapeutics has provided me with excellent service. I am extremely pleased with the quality of their products and the professionalism of their staff. They have exceeded my expectations and I will definitely be a returning customer.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="phusistherapeutics-com" data-lang="en"></div>
More widgets

About PHusis Therapeutics

PHusis is designing precision medicines using its proprietary computational modeling platform, PHuDock to rapidly identify inhibitors of proteins with regulatory PH-domains that drive cancer growth. The approach provides PHusis with the means of identifying drug leads more rapidly and in a cost effective manner. The result is, PHusis has built a pipeline of drug leads against some novel and critical cancer targets including PDK1, mutant KRAS and NRAS. Patients can be selected for treatment based on their mutational profile, eliminating unnecessary treatment of patients without the targets.